

Curtis R. Coughlin II, Ph.D., M.S., MBE, CGC, HEC-C

Associate Professor, Department of Pediatrics &
Center for Bioethics and Humanities
University of Colorado Anschutz Medical Campus
RC1 North, P18-4126, mail stop 8313
Aurora, Colorado, 80045, USA

Office: 303.724.3839
Mobile: 856.889.7374
Curtis.Coughlin@CUAnschutz.edu
Curtis.Coughlin@childrenscolorado.org

Education

- 1995-1999 Bachelor of Science in Biology
Geneva College, Beaver Falls, Pennsylvania
- 1999-2001 Master of Science in Genetic Counseling
Arcadia University, Glenside, Pennsylvania
- 2005-2010 Master of Bioethics
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
- 2017-2021 Doctor of Philosophy in Clinical Science
University of Colorado Anschutz Medical Campus, Aurora, Colorado

Academic appointments

- 2007-2010 Adjunct Professor, Genetic Counseling Program
Arcadia University, Glenside, Pennsylvania
- 2012-2017 Assistant Professor, Department of Pediatrics
University of Colorado School of Medicine, Aurora, Colorado
- 2013 -- Faculty Member, Genetic Counseling Graduate Program
University of Colorado Denver, Aurora, Colorado
- 2016 -- Associate Faculty (2016-2019), Faculty (2020 --)
Center for Bioethics and Humanities
University of Colorado Anschutz Medical Campus, Aurora, Colorado
- 2017 -- Associate Professor, Department of Pediatrics
University of Colorado School of Medicine, Aurora, Colorado

Professional positions

- 2001-2006 Genetic Counselor, Department of Maternal Fetal Medicine
Christiana Care Health System, Newark, Delaware
- 2006-2010 Genetic Counselor, Section of Biochemical Genetics
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- 2010 -- Genetic Counselor, Section of Genetics and Metabolism
Children's Hospital Colorado, Aurora, Colorado

2020 -- Ethics Consultant and Ethics Core Faculty
Children's Hospital Colorado, Aurora, Colorado

Honors, special recognitions, and awards

2015 Emmanuel Shapira Award, Society for Inherited Metabolic Disorders

- Awarded for the best research paper published in Molecular Genetics and Metabolism by a member of the Society for Inherited Metabolic Disorders

Membership in professional organizations

2000 -- National Society of Genetic Counselors

- Ethics Advisory Group (Member 2010-2012, Chair 2013-2015)
- Nominating Committee (2017)
- Director-at-large, Board of Directors (2017-2018)

2002 -- American Board of Genetic Counselors

- Item Writer, Certification Exam (2010-2012)
- Certification Exam Committee (2013-2015)

2013 -- Society for Inherited Metabolic Disorders

- Annual Meeting Planning Committee (2021-2023)
- Membership Engagement Committee (2021 --)

2014 -- American Society for Bioethics + Humanities

2019 -- Society for the Study of Inborn Errors of Metabolism

Major committee and service responsibilities

Local

2011 -- Member (2011-2019), Core faculty (2020 --)
Ethics committee, Children's Hospital of Colorado

- Annual conference planning committee (2015, 2022)
- Workgroup, Pediatric metabolic and bariatric surgery (2018-2020)
- Clinical ethics quality improvement (QI) and research (2020 --)
- Workgroup, Crisis standards of care (2020)
- Workgroup, Fetal precision medicine (2021 --)
- Workgroup, Interventions for neonates with Trisomy's 13 and 18 (2021 --)

2018 -- Colorado Center for Personalized Medicine
Collaboration between University of Colorado School of Medicine, University of Colorado Health, and Children's Hospital Colorado

- Ethics, Legal and Social Implications (ELSI) working group (2018 --)
- Biobank Enrollment And Results (BEAR) working group (2021 --)
- Pharmacogenetics Implementation Committee Colorado (PICColo) (2021 --)

2020 K to R (KTR) Transition Program
Colorado Clinical and Translational Science Institute, University of Colorado

Regional

2015-2016 (2015) Ethics Advisor, (2016) Ad hoc content expert – Ethics
Colorado Department Public Health and Environment

2021 Program committee and content expert
Cut, Paste, Delete: The Ethics of Gene Editing and Humanity's Hereditary Future
Webinar co-sponsored by Center for Bioethics and Humanities and Denver
Museum of Nature and Sciences' Institute of Science & Policy

National

2012 Ad hoc committee for the position of the NSGC: Genetic testing of minors
National Society of Genetic Counselors

2013 Ad hoc committee for the position of the NSGC: Incidental Findings
National Society of Genetic Counselors

2014-2021 Member, Consent And Disclosure Recommendations (CADRe) committee
The Clinical Genome Resource (ClinGen)

2018 Nominal group expert, VLCAD Nutritional Management Guidelines
Southeast Regional NBS & Genetics Collaborative
Genetic Metabolic Dietitians International
• Available at: https://southeastgenetics.org/npg/guidelines_vlcaad.phb

2019 -- Advisory committee member, UPenn Master's in Genetic Counseling Program
University of Pennsylvania (UPenn), Philadelphia, Pennsylvania

2020 -- Member, Practice Based Competencies (PBCs) task force
Accreditation Council for Genetic Counseling

International

2017 -- *ALDH7A1* variant curation (genetic cause of pyridoxine-dependent epilepsy)
(2017 --) Leiden Open Variation Database (<http://www.LOVD.nl/ALDH7A1>)
(2021 --) Human disease genes website (<https://humandiseasegenes.nl/>)

2021-2024 Scientific advisory board member, EJPRD CHARLIE consortium
CHANGing Rare disorders of LysInE (CHARLIE) metabolism

License and board certification

2002 Certified Genetic Counselor (CGC)
American Board of Genetic Counseling
• Recertification: 2012, 2017

2020 Healthcare Ethics Consulting Certification (HEC-C)
American Society for Bioethics + Humanities

Inventions, intellectual property, and patents

"6-oxopipicolinic acid quantitation by mass spectrometry." Regents of the University of Colorado
Inventors: Wempe MF, Van Hove JL, **Coughlin CR 2nd.**

- US provisional patent application No. 62/632,379, 19 Feb 2018
- PCT patent app No. PCT/US/19/18570, 19 Feb 2019

Review and referee workEditorial boards

2018 -- Review Editor, Neurogenetics: A Frontiers in Neurology journal

Grant review committees and study sections

2004-2005 Health Resources and Service Administration (HRSA)

2018 LifeArc Philanthropic Fund, London, United Kingdom

2020-2021 Colorado Clinical and Translational Science Institute, Pilot Program

2021 ZonMw Clinical Fellows (KlinischeFellows) program,
the Netherlands Organization for Health Research and Development

Ad hoc reviewer for journals, professional societies, or scientific meetings

2011 -- Ad hoc Manuscript Reviewer, Journal of Genetic Counseling

2014 -- Ad hoc Manuscript Reviewer, Journal of Human Nutrition and Dietetics

2014 -- Ad hoc Manuscript Reviewer, Annals of Internal Medicine

2014 -- Ad hoc Manuscript Reviewer, Journal of Inherited Metabolic Disease

2014 Ad hoc Book Reviewer, Oxford University Press

2015 -- Ad hoc Manuscript Reviewer, Journal of Pediatric Genetics

2015 -- Ad hoc Manuscript Reviewer, Applied & Translational Genomics

2015 Ad hoc Guideline Reviewer, American College of Medical Genetics & Genomics

2016 -- Ad hoc Manuscript Reviewer, Journal of Pediatric Intensive Care

2016 -- Ad hoc Manuscript Reviewer, BBA – Molecular Basis of Disease

2017 -- Ad hoc Manuscript Reviewer, Journal of Community Genetics

2017 -- Ad hoc Manuscript Reviewer, Journal of Pediatrics

2017 -- Ad hoc Manuscript Reviewer, BMC Medical Genetics

2017 -- Ad hoc Manuscript Reviewer, Journal of Biological Inorganic Chemistry

2018 -- Ad hoc Manuscript Reviewer, Cell Reports

2018 -- Ad hoc Manuscript Reviewer, Frontiers in Neurology

2018 -- Ad hoc Manuscript Reviewer, Journal of Pediatric Neurology

2019 -- Ad hoc Manuscript Reviewer, Scientific Reports

2019 -- Ad hoc Manuscript Reviewer, Orphanet Journal of Rare Diseases

2019 -- Ad hoc Manuscript Reviewer, Molecular Genetics and Metabolism

2019 -- Ad hoc Manuscript Reviewer, Developmental Medicine & Child Neurology

2019 -- Ad hoc Manuscript Reviewer, Bioanalysis

2019 -- Ad hoc Manuscript Reviewer, Therapeutic Advances in Neurological Disorders

2019 -- Ad hoc Manuscript Reviewer, Frontiers in Genetics

2020 -- Ad hoc Manuscript Reviewer, Metabolites

2020 -- Ad hoc Manuscript Reviewer, Pediatric Neurology

2020 -- Ad hoc Manuscript Reviewer, Biochimie

2020 -- Ad hoc Manuscript Reviewer, JIMD Reports

2021 -- Ad hoc Manuscript Reviewer, Frontiers in Nutrition

2021 -- Ad hoc Manuscript Reviewer, European Journal of Paediatric Neurology

2021 -- Ad hoc Manuscript Reviewer, BMC Medical Ethics

2021 Abstract review committee, SIMD 43rd Annual Meeting

Invited extramural lectures, presentations and visiting professorshipsCommercial or pharmaceutical audience, invited lectures

1. *Inborn errors of intermediary metabolism: An overview and prospects for treatment*. PTC Therapeutics. Presented to the R&D team and medical director (2010).
2. *Genetics and genomics: The current landscape of genetic testing*. Recordati Rare Diseases Group. Provided to medical and commercial team (2018).

Local conference, invited lectures

1. *An approach to the dysmorphic neonate: The importance of genetic counseling during the neonatal investigation*. Neonatology grand rounds, Thomas Jefferson University, Philadelphia, Pennsylvania (2005)
2. *Genetics and ethics: From eugenics to reproductive autonomy*. Ethics Elective, Temple University Medical School, Philadelphia, Pennsylvania (2006)
3. *Pyridoxine dependent epilepsy: Improving developmental outcome in a metabolic encephalopathy*. Section of Neurology, University of Colorado (2016)
4. *Pyridoxine dependent epilepsy: A common and treatable metabolic encephalopathy*. Section of Neurology. University of Colorado (2017)

Regional conference, invited lectures

1. *Risk Assessment and Common Genetic Syndrome, Incorporating Genetics into Obstetrical Care*. Christiana Care, Newark, Delaware (2003)
2. *Our Genes; Our Choices*. Adult Education Series, Elkton, Maryland (2003)
3. *How to present topics in genetics that will relate to your students' future*. Delaware Technical and Community College, Georgetown, Delaware (2004)
4. *Clinical Genetics: Introduction to the field of clinical genetics*. Delaware science teacher's continuing education, Dover, Delaware (2004; 2005)
5. *Genetics and ethics: Important partners or strange bedfellows*. Impact of Genetics on Healthcare, Jack F. Owens Campus, Georgetown, Delaware (2005)
6. *Direct to consumer testing: An ethical perspective*. Genetic Counseling Supervisor's meeting, Arcadia University, Glenside, Pennsylvania (2008)
7. *VLCAD deficiency: Pitfalls of newborn screening*. Mountain States Genetics Regional Collaborative. Aurora, Colorado (2011)
8. *Pyridoxine dependent epilepsy: Role of a lysine restricted diet*. Mountain States Genetics Regional Collaborative. Phoenix, Arizona (2013)
9. *Genetic testing: Benefits and burdens*. Children's Colorado Annual Ethics Conference 2015, Aurora, Colorado (2015)
10. *All about that base(pair): Can genetic testing reveal ethical concerns?* Semi-Annual Colorado Genetic Counseling Symposium, Aurora, Colorado (2015)
11. *Newborn screening: From PKU to personal genomics*. The 37th Annual Perinatal Clinical Update, Children's Hospital of Colorado, Aurora, Colorado (2016)
12. *PDE: A treatable epileptic encephalopathy*. Translational Approaches to Epilepsy Research. Skaggs School of Pharmacy and Pharmaceutical Sciences Annual Retreat. Breckenridge, Colorado (2017)
13. *Personal Genetics (what happens when families diagnose themselves/their children)*. 10th Annual Pediatric Advanced Practice Conference. University of Colorado College of Nursing, Colorado Rock Mountain NAPNAP, Children's Hospital Colorado, Aurora, CO (2020)
14. *Mandatory vaccinations: A case debated*. 24th Annual Ethics Conference, Children's Hospital Colorado, Aurora, CO (2020).

* Meeting cancelled due to the novel coronavirus disease COVID-19

National conference, invited lectures

1. *VLCAD deficiency: Examining the practicalities and pitfalls of NBS*. Genetics Rounds, Stanford University School of Medicine, Palo Alto, California (2009)
2. *Examining ethical implications of care in lethal conditions*. National Society of Genetic Counselors 31st Annual Education Conference, Boston, Massachusetts (2012)
3. *Triple therapy for pyridoxine dependent epilepsy*. The 39th Annual Meeting of the Society for Inherited Metabolic Disorders, Ponte Vedra Beach, Florida (2016)
4. *Genetic Counselors' Perspective on Constitutional Genomic Testing*. Cancer Genomics Consortium 2016 Summer Meeting. Denver, Colorado (2016)
5. *Exploring ethical, legal, and social implications of prenatal diagnostic exome sequencing*. National Society of Genetic Counselors 35th Annual Education Conference, Seattle, Washington (2016)
6. *Clinical studies in nonketotic hyperglycinemia (NKH)*. Rare Disease Day Conference. The Boler-Parseghian Center for Rare and Neglected Diseases at the University of Notre Dame. South Bend, Indiana (2017)
7. *Genetic testing of minors for adult onset conditions: An ethical perspective*. National Society of Genetic Counselors 36th Annual Education Conference. Columbus, Ohio (2017)
8. *Ethical issues in genetic counseling practice: Revising ethical principles in genomic medicine*. Center for Applied Genetics and Genomic Medicine. University of Arizona, Tucson, Arizona (2018)
9. *Life sustaining measures and lethal diagnosis: A model of shared decision making*. Integrated Genetics. Philadelphia, Pennsylvania (2018)
10. *Is low carnitine a problem? To supplement or not to supplement*. The 41st Annual Meeting of the Society for Inherited Metabolic Disorders, Bellevue, Washington (2019)
11. *Ethical issues in era of genomic medicine*. 8th Annual Sanford Imagenetics Genomic Medicine Symposium. Sanford Health. Sioux Falls, South Dakota (2019)
12. *Pyridoxine-dependent epilepsy: A treatable disorder of lysine metabolism*. Genetic Metabolic Dietitians International Conference. Austin, TX (2020)
* Meeting cancelled due to the novel coronavirus disease COVID-19

International conference, invited lectures

1. *Triple therapy and newborn screening for PDE*. The Pyridoxine-Dependent Epilepsy investigator meeting. BC Children's Hospital, Vancouver, British Columbia, Canada (2016)
2. *A novel biomarker for the diagnosis of pyridoxine-dependent epilepsy*. 5th International PDE Workshop. Amsterdam University Medical Center, Amsterdam, The Netherlands (2019)
3. *Ethical issues in genomic consent for high-risk patients*. 14th International Congress of Inborn Errors of Metabolism. Sydney, Australia (2021)
4. *Pyridoxine-dependent epilepsy: Towards newborn screening*. Newborn screening symposium. United for Metabolic Diseases. Amsterdam, The Netherlands (2022)

Teaching recordDidactic teaching, graduate, and medical school students

- | | |
|-----------|--|
| 2007-2010 | Biochemical and Developmental Genetics (Graduate students)
Course director and lecturer, Arcadia University |
| 2007-2010 | Ethical Issues in Genetic Counseling; (Graduate students)
Course director and lecturer, Arcadia University |

- 2007 The Role of Families in Contemporary Bioethics (Graduate students)
Lecturer, University of Pennsylvania School of Medicine
- 2008-2010 Reproduction Module – Ethical Issues in Reproduction (Medical students)
Lecturer, University of Pennsylvania School of Medicine
- 2011 -- Introduction to Clinical Research (Graduate students)
Lecturer (2011-2012); Co-director (2013); Director (2014-present)
University of Colorado Denver
- 2012-2013 Embryogenetics (Graduate students)
Lecturer, University of Colorado Denver
- 2013-2018 Public Health Genetics (Graduate students)
Lecturer, University of Colorado Denver
- 2013 -- Clinical Cytogenetics and Molecular Genetics (Graduate students)
Lecturer, University of Colorado Denver
- 2014 -- Human Inborn Errors of Metabolism (Graduate students)
Lecturer, University of Colorado Denver
- 2014-2019 Introduction to Ethics (Graduate students)
Lecturer, University of Texas Genetic Counseling Program at Houston
- 2015 -- Integrated Clinicians Course (Medical students)
Discussion group facilitator, University of Colorado School of Medicine
- Caring for Patients with Progressive Illness
 - Transition to Residency and Beyond
 - Shared Decision-making
- 2019 Ethics and Professional Conduct (Graduate students)
Lecturer, Bay Path University MS Genetic Counseling Program
- 2019 -- Molecules to Medicine (M2M) (Medical students)
Discussion group facilitator, University of Colorado School of Medicine
- Research ethics (Phase I)
- 2020 InterProfessional Education & Development (IPED) (AMC healthcare students)
Facilitator, University of Colorado School of Medicine
- 2021 Clinical Ethics (Certificate in health humanities and ethics)
Lecturer, Center for Bioethics and Humanities, University of Colorado

Didactic teaching (continuing education) and postgraduate education

- 2012 -- Metabolic University
- *Intoxication disorders* (2012, 2013)
 - *Fatty acid oxidation* (2012-13, 2016-21)
 - *Metabolic laboratory tests* (2013)
 - *Glutaric Aciduria type I* (2013-14)
 - *Anabolism* (2015)
 - *Urea Cycle Disorders* (2016-2019)
 - *Solid organ transplant as therapy for IEM* (2017-2020)
- 2014 -- *Genetics in the NICU*, Graduate Nurse Phase Class, Section of Neonatology
Children's Hospital of Colorado, Aurora, Colorado
- 2019 -- *Ethics and genetics*, Leadership Education in Neurodevelopmental Disabilities
University of Colorado Anschutz Medical Center, Aurora, Colorado
- 2020 -- *Pediatric ethics*, Second Year Fellowship Retreat (pediatric subspecialties)
Children's Hospital of Colorado, Aurora, Colorado
- 2020 -- *Amino acid disorders II: Lysine and vitamin B₆ metabolism*
Medical biochemical genetics fellows (available to trainees at 17 US programs)
Clinical Core Seminar Series, University of Colorado Anschutz Medical Campus
- 2021 *Pediatric ethics grand rounds*, Monthly seminar for all pediatric providers or staff
Children's Hospital of Colorado, Aurora, Colorado
- 2021 *Pyridoxine-dependent epilepsy is a treatable disorder of lysine metabolism*
Genetic Metabolic Dietitians International (GMDI) Webinar series

Qualifying examination committees

- 2014 Thuy-Mi Nguyn, Genetic Counseling M.S. Program (M.S. Candidate)
University of Colorado Denver, Aurora, Colorado

Committees concerned with medical and graduate student education*Graduate students in Genetic Counseling programs – capstone or thesis committee*

- 2007-2008 Carolyn Heuer, Genetic Counseling Program (M.S. Candidate)
Arcadia University, Glenside, Pennsylvania
- 2011-2012 Katie Golden-Grant, Genetic Counseling M.S. Program (M.S. Candidate)
University of Colorado Denver, Aurora, Colorado
- 2012-2013 Susana San Roman Rivera, Genetic Counseling M.S. Program (M.S. Candidate)
University of Colorado Denver, Aurora, Colorado
- 2013-2015 Thuy-Mi Nguyen, Genetic Counseling M.S. Program (M.S. Candidate)
University of Colorado Denver, Aurora, Colorado

- 2015-2016 Leah Rhodes, Genetic Counseling M.S. Program (M.S. Candidate)
University of Colorado Denver, Aurora, Colorado
- 2019-2020 Allie Morris, Augustana-Sanford Genetic Counseling Program (M.S. Candidate)
Augustana University, Sioux Falls, South Dakota
- 2019-2020 Maia Borensztein, MS Human Genetics and Genetic Counseling (M.S. Candidate)
Stanford University, Stanford, California
- 2021-2022 Lauren Walker, Human Genetics and Genetic Counseling (M.S. Candidate)
Thomas Jefferson University, College of Life Sciences, Philadelphia, PA

Medical students at the University of Colorado – mentor for the mentored scholar activity (MSA)

- 2021-2022 Madison Hanson, University of Colorado School of Medicine (M.D. Candidate)
University of Colorado Anschutz Medical Campus, Aurora, CO

Grants, financial support, active research studies

Grants, funded

U54HD061221 (NICHD) Gropman (PI) 09/17/19-07/31/24

Urea Cycle Disorders Consortium

The Urea Cycle Disorders Consortium focuses on the 8 related disorders essential for urea biosynthesis. The consortium is an international network of 16 academic centers that provide start-of-the-art care and conduct is innovative clinical research focused on urea cycle disorders.

Role: Co-investigator

Grants, pending

R21HD104952A (NICHD) **Coughlin** (PI) 09/01/21-08/31/23

Newborn screening and treatment monitoring for patients with pyridoxine-dependent epilepsy

The overall goal of this study is to establish a dried blood method to measure 6-oxo-pipecoalte in patients affected with pyridoxine-dependent epilepsy. This will be the basis for future newborn screening and evaluation of treatment efficacy.

Awaiting funding decision. Impact score: 26; Percentile: 9.0%

U54HD061221 - Pilot study Wilkening (PI) 01/01/22-12/31/22

Ability and satisfaction with social roles in adults with Urea Cycle Disorders (UCDs)

This is a pilot study with the goal to describe adult patients' perceived ability to fulfill age-appropriate social roles and the clinical and social factors that support patients in these endeavors. These results will be crucial to ensure future scientific studies and clinical trials have outcome measures that are relevant, sensitive and patient centered.

Role: Co-investigator

Grants, completed

R01HD058567 (NICHD) Tuchman (PI) 08/05/08-02/28/17

N-carbamylglutamate in the treatment of hyperammonemia

The overall objective of this project is to determine whether treatment of acute hyperammonemia with N-carbamyl-L-glutamate improves overall trajectory of ammonia.

Role: Co-investigator

UL1R001082 (NCATS) Sokol (PI)
 Child Maternal Health Pilot Grant **Coughlin** (pilot grant PI) 01/01/16-06/29/17
Dried blood spot screening for pyridoxine-dependent epilepsy
 The overall objective of the study is to establish a newborn screening method for pyridoxine-dependent epilepsy.

2UC4DK063821 (NIDDK) Rewers (PI) 03/01/03-05/01/18
The Environmental Determinants of Diabetes in the Young – Colorado Clinical Center
 The primary objectives are to identify infectious agents, dietary factors, environmental exposures that are associated with increased risk of autoimmunity and Type 1 diabetes
 Role: Co-investigator (07/01/16-10/31/17)

U54HD061221 (NIH) Batshaw (PI) 08/25/14-07/31/19
Urea Cycle Disorders Consortium
 The Urea Cycle Disorders Consortium is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research Network (RDCRN), supported through collaboration between the Office of Rare Diseases Research (ORDR), the National Center for Advancing Translational Science (NCAT S), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
 Role: Co-investigator

R01GM120772 (NIGMS) Kwok and Shaikh (MPIs) 09/22/16-05/31/20
Next Generation Mapping of Complex Genomic Regions involved in Recurrent Structural Variations
 The overall goal of this application is to analyze and map genomic regions containing segmental duplications, which mediate recurrent chromosomal rearrangements.
 Role: Co-investigator

Active research studies

Inborn errors of metabolism resulting in neurologic dysfunction

The overall focus of our research laboratory is to understand the role of metabolism in the phenotype of pyridoxine-dependent epilepsy, glutaric aciduria type I, and defects of pyridoxine metabolism. This work leverages our understanding of biochemistry to improve the diagnosis and treatment of patients with these devastating neurologic disorders.

Support for this work: <https://giving.cu.edu/fund/pyridoxine-dependent-epilepsy-pde-research>

PDE Consortium (www.pdeonline.org)

The PDE consortium is an international collaboration among clinicians, scientist, and families with the primary goal of improving the health outcome of individuals affected by PDE (PI: Clara van Karnebeek, the Netherlands). Among the ongoing research studies is the international registry for patients with pyridoxine-dependent epilepsy (PDE Registry), which is an observational natural history study. I serve as one of the PDE Consortium co-principal investigators and lead contact for US subjects enrolled in the PDE Registry.

Bibliography[Google Scholar](#): h-index = 23, i10-index = 39

Research publications [peer-reviewed]:

1. DeBerardinis RJ, **Coughlin CR 2nd**, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. *J Urol*. 2008 Dec;180(6):2620-3. PMID: 18951580
2. Kranick SM, Ganesh J, **Coughlin CR 2nd**, Licht DJ. Child neurology: a case illustrating the role of imaging in evaluation of sudden infant death. *Neurology*. 2009 Sep 15;73(11):e54-6. PMID: 19752447
3. Ficicioglu C, **Coughlin CR 2nd**, Bennett MJ, Yudkoff M. Very long-chain acyl-CoA dehydrogenase deficiency in a patient with normal newborn screening by tandem mass spectrometry. *J Pediatr*. 2010 Mar;156(3):492-4. PMID: 20056241
4. **Coughlin CR 2nd**, Ficicioglu C. Genotype-phenotype correlations: sudden death in an infant with very-long-chain acyl-CoA dehydrogenase deficiency *J Inher Metab Dis*. 2010 Dec;33 Suppl 3:129-131. PMID: 20107901
5. **Coughlin CR 2nd**, Krantz ID, Schmitt ES, Zhang S, Kerr DS, Ganesh J. Somatic mosaicism for PDHA1 mutation in a male with pyruvate dehydrogenase complex deficiency. *Mol Genet Metab*. 2010 Jul;100(3):296-299. PMID: 20462777
6. Sampson MG, **Coughlin CR 2nd**, Kaplan P, Conlin LK, Meyers KE, Zackai EH, Spinner NB, Copelovitch L. Evidence for a recurrent microdeletion at chromosome 16p11.2 associated with congenital anomalies of the kidney and urinary tract (CAKUT) and Hirschsprung disease. *Am J Med Genet A*. 2010 Oct;152A(10):2618-2622. PMID: 20799338
7. van Karnebeek CDM, Hartmann H, Jaggumantri S, Bok L, Cheng B, Connolly M, **Coughlin CR 2nd**, Das AM, Gospe S, Jackobs C, van der Lee J, Mercimek-Mahmutoglu S, Meyer U, Struys E, Sinclair G, Van Hove J, Collett JP, Plecko BR, Stockler S. Lysine restricted diet for pyridoxine-dependent epilepsy: First evidence and future trials. *Mol Genet Metab*. 2012 Nov;107(3):335-344. PMID: 23022070
8. Stence NV, **Coughlin CR 2nd**, Fenton LZ, Thomas JA. Distinctive pattern of restricted diffusion in a neonate with molybdenum cofactor deficiency. *Pediatr Radiol*. 2013 Jul;43(7):882-5. PMID: 23250031
9. **Coughlin CR 2nd**, Hyland K, Randall R, Ficicioglu C. Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: A case report. *JIMD Rep*. 2013;10:53-56. PMID: 23430801
10. Yu HC, Sloan JL, Scharer G, Brebner A, Quintana AM, Achilly NP, Manoli I, **Coughlin CR 2nd**, Geiger EA, Schneck U, Watkins D, Suormala T, Van Hove JLK, Fowler B, Baumgartner MR, Rosenblatt DS, Venditti CP, Shaikh TH. An X-linked Cobalamin Disorder Caused by Mutations in Transcriptional Coregulator *HCFC1*. *Am J Hum Genet*. 2013 Sep 5;93(3):506-514. PMID: 24011988
11. Baker PR 2nd, Friederich MW, Swanson MA, Shaikh T, Bhattacharya K, Scharer GH, Aicher J, Creadon-Swindell G, Geiger E, Maclean KN, Lee WT, Deshpande C, Freckmann ML, Shih LY, Wasserstein M, Rasmussen MB, Lund AM, Procopis P, Cameron JM, Robinson BH, Brown GK, Brown RM, Compton AG, Dieckmann CL, Collard R, **Coughlin CR 2nd**, Spector E, Wempe MF, Van Hove JL. Variant non-ketotic hyperglycinemia is caused by mutations in *LIAS*, *BOLA3* and the novel gene *GLRX5*. *Brain*. 2014 Feb; 137(Pt 2):366-379. PMID:24334290
12. van Karnebeek CDM, Stockler-Ipsiroglu S, Jaggumantri S, Assmann B, Baxter P, Buhas D, Bok LA, Cheng B, **Coughlin CR 2nd**, Das AM, Giezen A, Al-Hertain W, Ho G, Meyer U,

- Mills P, Plecko B, Struys E, Ueda K, Albersen M, Verhoeven N, Gospe SM Jr, Gallagher RC, Van Hove JKL, Hartmann H. Lysine-restricted diet as adjunct therapy for pyridoxine-dependent epilepsy: The PDE consortium consensus recommendations. *JIMD Rep.* 2014; 15:1-11. PMID: 24748525
13. Chatfield KC, **Coughlin CR 2nd**, Friederich MW, Gallagher RC, Hesselberth JR, Lovell MA, Ofman R, Swanson MA, Thomas JA, Wanders RJA, Wartchow EP, Van Hove JL. Mitochondrial energy failure in HSD10 disease is due to defective mtDNA transcript processing. *Mitochondrion.* 2015 Mar; 21:1-10. PMID: 25575635
 14. **Coughlin CR 2nd***, Scharer GH*, Friederich M, Geiger EA, Creadon-Swindell G, Yu HC, Collins AE, Vanlander AV, Van Coster R, Powell CA, Swanson MA, Minczuk, Van Hove JLK, Shaikh TH. Mutations in the mitochondrial cysteinyl-tRNA synthase gene, *CARS2*, lead to a severe epileptic encephalopathy and complex movement disorder. *J Med Genet.* 2015 Aug;52(8):532-40. PMID: 25787132
 15. **Coughlin CR 2nd**, van Karnebeek CDM, Al-Hertani W, Shuen AY, Jaggumantri S, Jack RM, Gaughan S, Burns C, Mirsky DM, Gallagher RC, Van Hove JLK. Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine dependent epilepsy: Neurodevelopmental outcome. *Mol Genet Metab* 2015 Sep-Oct; 116(1-2):35-43. PMID: 26026794
 16. Ferdinandusse S, Friederich MW, Burlina A, Ruiten JPN, **Coughlin CR 2nd**, Dishop MK, Gallagher RC, Bedoyan JK, Vaz FM, Waterham HR, Gowan K, Chatfield K, Bloom K, Bennett MJ, Elpeleg O, Van Hove JL, Wanders RJ. Clinical and biochemical characterization of four patients with mutations in *ESCH1*. *Orphanet J Rare Dis.* 2015 Jun 18;10(1)79. PMID: 26081110
 17. Swanson MA, **Coughlin CR 2nd**, Scharer GH, Szerlong HJ, Bjoraker KJ, Spector EB, Creadon-Swindell G, Mahieu V, Matthijs G, Hennermann JB, Applegarth DA, Toone JR, Tong S, Williams K, Van Hove JL. Biochemical and Molecular Predictors for Prognosis in Nonketotic Hyperglycinemia. *Ann Neurol.* 2015 Oct;78(4):606-18. PMID: 26179960
 18. Weber DR, **Coughlin CR 2nd**, Brodsky J, Lindstrom K, Ficicioglu C, Kaplan P, Freehauf C, Levine MA. Low bone mineral density is a common finding in patients with Homocystinuria. *Mol Genet Metab.* 2016 Mar, 117(3):351-354. PMID: 26689745
 19. Bjoraker KJ, Swanson MA, **Coughlin CR 2nd**, Christodoulou J, Tan ES, Ferguson M, Dyack S, Ahmad A, Friederich MW, Spector E, Creadon-Swindell G, Hodge MA, Gaughan S, Burns C, Van Hove JLK. Neurodevelopmental Outcome and Treatment Efficacy of Benzoate and Dextromethorphan in Siblings with Attenuated Nonketotic Hyerglycinemia. *J Pediatr.* 2016 Mar;170:234-239. PMID: 26749113
 20. Yu HC*, **Coughlin CR***, Geiger EA, Salvador BJ, Elias ER, Cavanaugh JL, Chatfield KC, Miyamoto SD, Shaikh TH. Discovery of a potentially deleterious variant in *TMEM87B* in a patient with a hemizygous 2q13 microdeletion suggests a recessive condition characterized by severe congenital heart disease and restrictive cardiomyopathy. *Cold Spring Harb Mol Case Stud.* 2016 May;2(3) PMID: 27148590
 21. van Karnebeek CDM, Tiebout SA, Niermeijer J, Poll-The BT, Ghani A, **Coughlin CR 2nd**, Van Hove JLK, Richter JW, Christen HJ, Gallagher R, Hartmann H, Stockler-Ipsiroglu S. Pyridoxine-Dependent Epilepsy: an expanding clinical spectrum. *Pediatr Neurol.* 2016 Jun;59:6-12. PMID: 26995068
 22. **Coughlin CR 2nd**, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Väisänen ML, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Rahikkala E, Moilanen

- J, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vinaey-Saban C, Scharer GH, Van Hove JLK. The genetic basis of classical nonketotic hyperglycinemia due to mutations in *GLDC* and *AMT*. *Genet Med*. 2017 Jan;19(1):104-111. PMID: 27362913
23. Beard L, Wymore E, Fenton L, **Coughlin CR**, Weisfeld-Adams JD. Lethal neonatal hyperammonemia in severe ornithine transcarbamylase (OTC) deficiency compounded by large hepatic portosystemic shunt. *J Inher Metab Dis*. 2017 Jan;40(1):159-160. PMID 27832417
 24. Friederich MW, Erdogan AJ, **Coughlin CR 2nd**, Elos M, Jiang H, O'Rourke C, Lovell M, Wartchow E, Gowan K, Chatfield KC, Chick WS, Spector E, Van Hove JLK, Riemer J. Mutations in accessory subunit NDUFB10 result in isolated complex I deficiency due to incomplete assembly of complex I holoenzyme. *Hum Mol Genet*. 2017 Feb 15;26(4):702-716. PMID: 28040730
 25. Wortmann SB, Chen MA, Colombo R, Pontoglio A, Alhaddad B, Botto LD, Yuzyuk T, **Coughlin CR**, Descartes M, Grunewald S, Kyriss MN, Marnada B, Mills PB, Pitt J, Potente C, Reid ES, Rodenburg R, Kluijtmans LA, Sampath S, Thomas JA, Waters PJ, White SM, Pai EF, Wevers RA, Tiller GE. Mild orotic aciduria in UMPS heterozygotes: A metabolic finding without clinical consequences. *J Inher Metab Dis*. 2017 May;40(3):423-431. PMID: 28205048
 26. Scalais E, Osterheld E, Weitzel C, De Meirleir L, Mataigne F, Martens G, Shaikh TH, **Coughlin CR 2nd**, Yu HC, Swanson M, Friederich MW, Scharer G, Helbling D, Wendt-Andrea J, Van Hove JL. X-linked cobalamin disorder (HCFC1) mimicking nonketotic hyperglycinemia with increased both cerebrospinal fluid glycine and methylmalonic acid. *Pediatr Neurol* 2017 Jun;71:65-69. PMID: 28363510
 27. Ormond KE, Hallquist MLG, Buchanan AH, Dondanville D, Cho MK, Smith M, Roche M, Brothers KB, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy HP, Raskin M, Stosic M, Uhlmann W, Wain KE, Currey E, Faucett WA. Developing a conceptual, reproducible, rubric-based approach to consent and result disclosure for genetic testing by clinicians with minimal genetics background. *Genet Med*. 2019 Mar;21(3):727-735. PMID: 29976988
 28. **Coughlin CR 2nd**^{*,†}, Swanson MA^{*}, Spector E, Meeks NJL, Kronquist KE, Aslamy M, Wempe MF, van Karnebeek CDM, Gospe SM Jr, Aziz VG, Tsai BP, Gao H, Nagy PL, Hyland K, van Dooren SJM, Salomons GS, Van Hove JLK. The genotypic spectrum of *ALDH7A1* mutations resulting in pyridoxine dependent epilepsy: A common epileptic encephalopathy. *J Inher Metab Dis*. 2019 Mar;42(2):353-361. PMID: 30043187
 29. Ah Mew N, Cnaan A, McCarter R, Choi H, Glass P, Rice K, Scavo L, Gillespie CW, Diaz GA, Berry GT, Wong D, Konczal L, McCandless SE, **Coughlin CR 2nd**, Weisfeld-Adams JD, Ficicioglu C, Yudkoff M, Enns GM, Lichter-Konecki U, Gallagher R, Tuchman M. Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: Lessons from the N-Carbamylglutamate Consortium. *Transl Sci Rare Dis*. 2018 Dec 20;3(3-4):157-170. PMID: 30613471
 30. Wempe MF, Kumar A, Kumar V, Choi YJ, Swanson MA, Friederich MW., Hyland K, Yue WW, Van Hove JLK^{*}, **Coughlin CR 2nd**^{*,†}. Identification of a novel biomarker for pyridoxine-dependent epilepsy: Implications for newborn screening. *J Inher Metab Dis*. 2019 May;42(3):565-574. PMID: 30663059
 31. Stence NV, Fenton LZ, Levek C, Tong S, **Coughlin CR 2nd**, Hennermann JB, Wortmann SB, Van Hove JLK. Brain imaging in classic nonketotic hyperglycinemia: Quantitative

- analysis and relation to phenotype. *J Inherit Metab Dis.* 2019 May;42(3):438-450. PMID: 30737808
32. Berry SA, **Coughlin CR 2nd**, McCandless S, McCarter R, Seminara J, Yudkoff M, Lemons C. Developing interactions with industry in rare diseases: Lessons learned and continuing challenges. *Genet Med.* 2020 Jan;22(1):219-226. PMID: 31337884
 33. Damaerel W, Mostovoy Y, Yilmaz F, Vervoort L, Pastor S, Hestand MS, Swillen A, Vergaelen E, Geiger EA, **Coughlin CR**, Chow SK, McDonald-McGinn D, Morrow B, Kwok PY, Xiao M, Emanuel BS, Shaikh TH, Vermeesch JR. The 22q11 low copy repeats are characterized by unprecedented size and structure variability. *Genome Res.* 2019 Sep;29(9):1389-1401. PMID: 31481461
 34. Friederich MW, Elias AF, Kuster A, Laugwitz L, Larson AA, Landry AP, Ellwood-Digel L, Mirsky DM, Dimmock D, Haven J, Jiang H, MacLean KN, Styren K, Schoof J, Goujon L, Lefrancios T, Friederich M, **Coughlin CR 2nd**, Banerjee, Haack TB, Van Hove JLK. Pathogenic variants in SQOR encoding sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease. *J Inherit Metab Dis.* 2020 Sep;43(5):1024-1036. PMID: 32160317
 35. Reyes-Nava NG, Yu HC, **Coughlin CR 2nd**, Shaikh TH, Qunitana AM. Abnormal expression of GABA_A receptor sub-units and hypomotility upon loss of *gabral* in zebrafish. *Biol Open.* 2020 Apr 13;9(4). PMID: 32205311
 36. Moore JM, Glover JJ, Jackson BM, **Coughlin CR 2nd**, Kelsey MM, Inge TH, Boles RE. Development and application of an ethical framework for pediatric metabolic and bariatric surgery evaluation. *Surg Obes Relat Dis.* 2021 Feb; 17(2):425-433. PMID: 33191162
 37. Bernstein L, **Coughlin CR**, Drumm M, Yannicelli S, Rohr F. Inconsistencies in nutritional management of glutaric aciduria type 1: An international survey. *Nutrients.* 2020 Oct 16;12(10):E3162. PMID: 33081139
 38. **Coughlin CR 2nd**^{*†}, Tseng LA^{*}, Abdenur JE, Ashmore C, Boemer F, Bok LA, Boyer M, Buhas D, Clayton PT, Das A, Dekker H, Evangeliou A, Feillet F, Footitt EJ, Gospe SM Jr, Hartman H, Kara M, Kristensen E, Lee J, Lilje R, Longo N, Lunsing RJ, Pearl PL, Piazzon F, Plecko B, Saini AG, Santra S, Sjarif DR, Stockler-Ipsiroglu S, Striano P, Van Hove JLK, Verhoeven-Duif NM, Wijburg FA, Zuberi SM, van Karnebeek CDM[†]. Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α -aminoacidic semialdehyde dehydrogenase deficiency. *J Inherit Metab Dis.* 2021 Jan;44(1):178-192. PMID: 33200442
 39. Mostovoy Y, Yilmaz F, Chow SK, Chu C, Lin C, Geiger EA, Meeks NJL, Chatfield KC, **Coughlin CR**, Surti U, Kwok PY, Shaikh TH. Genome regions associated with microdeletion/microduplication syndromes exhibit extreme diversity of structural variation. *Genetics.* 2021 Feb 9;21(2):iyaa038 PMID: 33724415
 40. Hallquist MLG, Tricou EP, Ormond KE, Savatt JM, **Coughlin CR 2nd**, Faucet WA, Hercher L, Levy HP, O'Daniel JM, Peay HL, Stosic M, Smith M, Uhlmann WR, Wand H, Wain KE, Buchanan AH. Application of a framework to guide genetic testing communication across clinical indications. *Genome Med.* 2021 Apr 29;13(1):71. PMID: 33926532
 41. Strijker M, Tseng LA, van Avezaath LK, Oude Luttikhuis MAM, Ketelaar T, **Coughlin CR 2nd**, Coenen MA, van Spronsen FJ, Williams M, de Vries MC, Westerlaan HE, Bok LA, van Karnebeek CD, Lunsing RJ. Cognitive and neurological outcome of patients in the Dutch pyridoxine-dependent epilepsy (PDE-ALDH7A1) cohort, a cross-sectional study. *Eur J Paediatr Neurol.* 2021 Jun 7;33:112-120. PMID: 34153871

42. Kripps KA, Baker PR, Thomas JA, Skillman HE, Bernstein L, Gaughan S, Burns C, **Coughlin CR 2nd**, McCandless SE, Larson AA, Kochar A, Stillman CF, Wymore EM, Hendricks EG, Woontner M, Van Hove JLK. REVIEW: Practical strategies to maintain anabolism by intravenous nutritional management in children with inborn metabolic diseases. *Mol Genet Metab.* 2021 Jul;133(3):231-241. PMID: 33985889
43. Ormond KE, Borenstein MJ, Hallquist MLG, Buchanan AH, Faucett WA, Peay HL, Smith ME, Tricou EP, Uhlmann WR, Wain KE, **Coughlin CR 2nd**, On behalf of the clinical genome CADRe workgroup. Defining the critical components of informed consent for genetic testing. *J Pers Med.* 2021 11(12):1304. PMID: 34945775

Invited reviews [peer-reviewed]

44. **Coughlin CR 2nd**, Scharer GH, Shaikh TH. Clinical impact of copy number variation analysis using high-resolution microarray technologies: Advantages, limitations, and concerns. *Genome Med.* 2012 Oct 30;4(10):80. PMID: 23114084
45. Van Hove J, **Coughlin C 2nd**, Scharer G. Glycine Encephalopathy. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K (eds.). *GeneReviews* [Internet] Seattle (WA): University of Washington, Seattle; 1993-2013, 2002 Nov 14 [updated 2013 Jul 11]. PMID: 20301531
46. Van Hove J, **Coughlin C 2nd**, Swanson M, Hennermann JB. Nonketotic Hyperglycinemia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds.). *GeneReviews* [Internet] Seattle (WA): University of Washington, Seattle; 1993-2019, 2002 Nov 14 [updated 2019 May 23]. PMID: 20301531
47. Faucett WA, Peay H, **Coughlin CR 2nd**. Genetic testing: Consent and result disclosure for primary care providers. *Med Clin North Am.* 2019 Nov; 103(6):967-976. PMID: 31582007

Consortium papers [peer-reviewed]

48. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS, **ClinGen**. ClinGen – the Clinical Genome Resource. *N Engl J Med* 2015 Jun 4;372(23):2235-42. PMID: 26014595
(I am one of 212 collaborators listed under ClinGen)
49. Burrage LC, Sun Q, Elsea SH, Jiang NM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G; **Members of the Urea Cycle Consortium**, Lee BH. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. *Hum Mol Genet.* 2015 Nov 15;24(22):6417-27. PMID 26358771
(I am one of 26 collaborators listed under Urea Cycle Consortium)
50. Waisbren SE, Gropman AL, **Members of the Urea Cycle Consortium**, Batshaw ML. Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium. *J Inherit Metab Dis.* 2016 Jul; 39(4):573-84. PMID 27215558
(I am one of 25 collaborators listed under Urea Cycle Consortium)
51. Waisbren SE, Cuthbertson D, Burgard P, Holbert A, McCarter R, Cederbaum S, **Members of the Urea Cycle Disorders Consortium**. Biochemical markers and neuropsychological function in distal urea cycle disorders. *J Inherit Metab Dis.* 2018 Jul;41(4):657-667. PMID 29423830
(I am one of 28 collaborators listed under Urea Cycle Disorders Consortium)

52. Posset R, Garbade SF, Boy N, Burlina AB, Dionisi-Vici C, Dobbelaere D, Garcai-Cazorla A, de Lonlay P, Teles EL, Vara R, Ah Mew N, Batshaw ML, Baumgartner MR, McCandless S, Seminara J, Summar M, Hoffmann GF, Kölker S, Burgard P; **Additional individual contributors of the UCDC and the E-IMD consortium**. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders – a successful strategy for clinical research of rare diseases. *J Inher Metab Dis*. 2019 Jan;42(1):93-106. PMID: 30740724
(I am one of 51 collaborators listed under UCDC or E-IMD)
53. Buerger C, Garbade SF, Dietrich Alber F, Waisbren SE, McCarter R, Kölker S, Burgard P, on behalf of the **Urea Cycle Disorders Consortium**. Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domain-specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. *J Inher Metab Dis*. 2019 Jan;42(1):93-106. PMID: 30671983
(I am one of 27 collaborators listed under Urea Cycle Disorders Consortium)
54. Posset R, Gropman AL, Nagamani SCS, Burrage L, Bedoyan JK, Wong D, Berry GT, Baumgartner MR, Yudkoff M, Zielonka M, Hoffmann GF, Burgard P, Schulze A, McCandless SE, Garcia-Cazorla A, Seminara S, Garbade SF, Kölker S for the **UCDC and the E-IMD consortia study group**. Impact of diagnosis and therapy on cognitive function in urea cycle disorders. *Ann Neurol*. 2019 Jul;86(1):116-128. PMID: 31018246
(I am one of 26 collaborators listed under UCDC)
55. Burrage LC, Thistlethwaite L, Stroup BM, Sun Q, Miller MJ, Nagamani SCS, Craigen W, Scaglia, F, Sutton VR, Graham B, Kennedy AD, **Members of the UCDC**, Milosavljevic A, Lee BH, Elsea SH. Untargeted metabolic profiling reveals multiple pathway perturbations and new clinical biomarkers in urea cycle disorders. *Genet Med*. 2019 Sep;21(9):1977-1986. PMID: 30670878
(I am one of 26 collaborators listed under UCDC)
56. Zielonka M, Kölker S, Gleich F, Stutzenberger N, Nagamani SCS, Gropman AL, Hoffmann GF, Garbade SF, Posset R, **Urea Cycle Disorders Consortium (UCDC)** and the European Registry and Network for Intoxication type Metabolic Diseases (E-IMD) Consortia Study Group. Early prediction of phenotypic severity in Citrullinemia type 1. *Ann Clin Transl Neurol*. 2019 Sep;6(9):1858-1871. PMID: 31469252
(I am one of 26 collaborators listed under UCDC)
57. Burrage LC, Madan S, Li X, Ali S, Mohammad M, Stroup BM, Jiang MM, Cela R, Bertin T, Jin Z, Dai J, Guffey D, Finegold M, **Members of the Urea Cycle Disorders Consortium (UCDC)**, Nagamani S, Minard CG, Marini J, Masand P, Schady D, Shneider BL, Leung DH, Bali D, Lee B. Chronic liver disease and impaired hepatic glycogen metabolism in arginosuccinate lyase deficiency. *JCI Insight*. 2020 Feb 27;5(4):e132342. PMID: 31990680
(I am one of 65 collaborators listed under UCDC)
58. Posset R, Garbade SF, Gleich F, Gropman AL, de Lonlay P, Hoffmann GF, Garcia-Cazorla A, Nagamani SCS, Baumgartner MR, Schulze A, Dobbelaere D, Yudkoff M, Kölker S, Zielonka M, **Urea Cycle Disorders Consortium (UCDC)**, European registry and network for Intoxication type Metabolic Diseases (E-IMD). Long-term effects of medical management on growth and weight in individuals with urea cycle disorders. *Sci Rep*. 2020 Jul 20;10(1):11948. PMID: 3268 6765
(I am one of 20 collaborators listed under UCDC)

59. Lerner S, Eilam R, Adler L, Baruteau J, Kreiser T, Tsoory M, Brandis A, Mehlman T, Ryten M, Botia JA, Garcia Ruiz S, Cisterna Garcia A, Dionisi-Vici C, Ranucci G, Spada M, Mazkereth R, McCarter R, Izem R, Balmat TJ, Richesson R, **Members of the UCDC**, Gazit E, Nagamani SCS, Erez A. ASL deficiency in ALDH1A1⁺ neurons in the substantia nigra metabolically promotes neurodegenerative phenotypes. *Hum Genet.* 2021 Oct;140(10):1471-1485. PMID: 34417872
(I am one of 26 collaborators listed under UCDC)

*These authors contributed equally

†Corresponding author

Book chapters, invited articles, and reviews in non-peer reviewed journals

1. **Coughlin CR 2nd** (2009) Prenatal choices: genetic counseling for variable genetic disease. In: V. Ravitsky, A. Fiester & A.L. Caplan (eds.). *Penn guide to bioethics*. pp. 415-424. New York, NY: Springer Publishing Company
2. Kaplan P, Fitzgerald KK, **Coughlin CR 2nd** (2012) Ehlers-Danlos syndrome. In: W. R. Heymann, B.E. Anderson, C. Hiynor & S.R. Lessin (eds.). *Clinical Decision Support: Dermatology*.
3. **Coughlin CR 2nd** (2014) These are not the genes you are looking for: Incidental findings identified as a result of genetic testing. In: J.L. Berliner (ed). *Ethical dilemmas in genetics: Exploring genetic counseling principles through case scenarios*. pp 117-134. New York, NY: Oxford University Press.
4. Van Hove JLK, **Coughlin CR** (2014) Nonketotic hyperglycinemia. In: GF Hoffmann and N Blau (eds). *Congenital Neurotransmitter Disorders: A clinical approach*. New York, NY: Nova Scientific Publishers, Inc.
5. **Coughlin CR 2nd** (2015) Laboratory Evaluations in Inherited Metabolic Diseases. In: L Bernstein, F Rohr, J Helm (eds). *Nutritional Treatment of Inherited Metabolic Diseases: Lessons from Metabolic University*. pp. 75-88. New York, NY: Springer Publishing Co
6. **Coughlin CR 2nd** (2015) Glutaric Aciduria Type I: Diagnosis and Management. In: L Bernstein, F Rohr, J Helm (eds). *Nutritional Treatment of Inherited Metabolic Diseases: Lessons from Metabolic University*. pp. 203-210. New York, NY: Springer Publishing Co
7. Van Hove JKL, Hennermann J, **Coughlin CR 2nd** (2016) Nonketotic hyperglycinemia (glycine encephalopathy) and lipoate deficiency disorders. In: Saudubray JM, Baumgartner MR & Walter JH (eds). *Inherited Metabolic Diseases – Treatment and Outcome 6th Ed.* pp. 349-356. Berlin, Heidelberg, Springer-Verlag Publishing Company.
8. Hennermann JB, Van Hove JKL, **Coughlin CR 2nd** (2018). Glycine Encephalopathy and epilepsy. In Pearl PL (ed). *Inherited Metabolic Epilepsies – Second Edition*. pp. 353-363. New York, NY: Demos Medical Publishing - Springer Publishing Company.
9. **Coughlin CR 2nd** (2020) Ethics of Genetic Research. In: Ragin & Keenan (eds). *Handbook of Research Methods in Health Psychology*. pp. 99-113. New York, NY: Routledge Publishing - A Taylor & Francis Publishing Company
10. Van Hove JLK, **Coughlin CR 2nd**, Swanson MA. (2021) Disorders of glycine metabolism. In Blau N, Dionisi-Vici C, Ferreira C, Vianey-Saban C & van Karnebeek CD (eds). *Physician's Guide to the Diagnosis, Treatment, and Follow-up of Inherited Metabolic Diseases*. pp***. Berlin, Heidelberg, Springer-Verlag Publishing Company.

11. **Coughlin CR 2nd**. Laboratory Evaluations in Inherited Metabolic Diseases. In: L Bernstein, F Rohr, J Helm (eds). *Nutritional Treatment of Inherited Metabolic Diseases: Lessons from Metabolic University*. pp. ***. New York, NY: Springer Publishing Co. *Expected publication date 2022*
12. **Coughlin CR 2nd**. Glutaric Aciduria Type I: Diagnosis and Management. In: L Bernstein, F Rohr, J Helm (eds). *Nutritional Treatment of Inherited Metabolic Diseases: Lessons from Metabolic University*. pp. ***. New York, NY: Springer Publishing Co Company. *Expected publication date 2022*
13. **Coughlin CR 2nd**. Fatty Acid Oxidation Disorders. In: L Bernstein, F Rohr, J Helm (eds). *Nutritional Treatment of Inherited Metabolic Diseases: Lessons from Metabolic University*. pp. ***. New York, NY: Springer Publishing Co Company. *Expected publication date 2021*
14. **Coughlin CR 2nd**, Ormond K. Ethical and legal issues. In A guide to genetic counseling. In: Schuette JL, Yashar B., Pan V, Wain K (eds). *A guide to Genetic Counseling. 3rd Edition*. pp***. Hoboken, NJ: Wiley-Blackwell. *Expected publication date 2023*.

Non-published documents, reports, research or policy papers, lay press articles

1. Nonketotic Hyperglycinemia. National Organization for Rare Disorders. Updated 2016
 - Available at: <https://rarediseases.org/rare-diseases/nonketotic-hyperglycinemia/>

Letters to the editor, editorial commentary, and obituary

1. Swanson MA, **Coughlin CR 2nd**, Van Hove JLK. Corrigendum: Biochemical and Molecular Predictors for Prognosis in Nonketotic Hyperglycinemia. Swanson MA et al. *Ann Neurol* 2015;78:606-618. *Ann Neurol*. 2016 Mar;79(3):505. PMID: 26969502
2. **Coughlin CR 2nd**, Swanson MA, Spector EB, Kronquist KE, Van Hove JL. Comment on Late-Onset Nonketotic Hyperglycinemia with a Heterozygous Novel Point Mutation of the GLDC Gene. *Pediatr Neurol*. 2018 Feb;79:e1. PMID: 29239742
3. **Coughlin CR 2nd**, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Väisänen ML, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Rahikkala E, Moilanen JS, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vianey-Saban C, Scharer GH, Van Hove JLK. CORRIGENDUM: The genetic basis of classical nonketotic hyperglycinemia due to mutations in GLDC and AMT. *Genet Med*. 2018 Sep;20(9):1098. PMID: 29300369
4. **Coughlin CR 2nd**. Pyridoxine-dependent epilepsy is more than just epilepsy. *Dev Med Child Neurol*. 2020 Mar;62(3):268. PMID: 31763687
5. Van Hove JLK, Thomas JA, McCandless SE, Woontner M, **Coughlin C**. In memoriam (Stephen I. Goodman, MD). *J Inherit Metab Dis*. 2021 Jan;44(1):26-287. PMID: 33354834

Scientific abstracts published or presented at scientific meetings, competitive

1. Heuer CB, Levin ER, **Coughlin CR 2nd**, Conway LJ. Direct-to-Consumer genetic testing: Genetic Counselors' attitudes and practices. Presented at the Mendel Symposium at Villanova University. Sept 2008, Villanova, Pennsylvania (Platform)
2. Heuer CB, Levin E, **Coughlin C**, Conway L. Direct-to-consumer genetic testing: Genetic counselors' attitudes and practices. Presented at the 27th Annual Education Conference of the National Society of Genetic Counselors. Oct 2008, Los Angeles, California (Poster). *J Genet Counsel* 2008;17(6):576.

3. **Coughlin CR 2nd**, Li FY, Wong LJ, Ganesh J. Novel duplication in the *PDHAI* gene in a family with 3 variably affected females with pyruvate dehydrogenase deficiency. Presented at the annual meeting of The American Society of Human Genetics. Nov 2008, Philadelphia, Pennsylvania. (Poster)
4. Ficicioglu C, **Coughlin CR 2nd**, Yudkoff M. Very-long-chain acyl-CoA dehydrogenase deficiency in two patients with normal newborn screening by tandem mass spectrometry. Presented at the annual meeting of The American Society of Human Genetics. Nov 2008, Philadelphia, Pennsylvania (Poster)
5. **Coughlin CR 2nd**, Haldeman-Englert C, Krantz ID, Schmitt ES, Zhang S, Kerr DS, Ganesh J. Somatic Mosaicism for *PDHAI* Mutations in a Male with Pyruvate Dehydrogenase Deficiency. Presented at the 11th International Congress of Inborn Errors of Metabolism. Sept 2009, San Diego, California (Poster). *Mol Genet Metab* 2009 Sept; 98(1-2):98.
6. Ganesh J, Mucha – Le Ny B, Deardorff M, **Coughlin C**, Spinner N, Yudkoff M. Ornithine Carbamylase deficiency complicated by deletion of contiguous genes on Xp. Presented at the 11th International Congress of Inborn Errors of Metabolism. September 2009, San Diego, California (Poster). *Mol Genet Metab* 2009 Sept; 98(1-2):147
7. Kallish S, Rand E, **Coughlin C 2nd**, Fitzgerald K, Ganesh J. Successful orthotopic liver transplantation in a patient with Complex IV deficiency. Presented at the annual meeting Mitochondrial Medicine 2009: Capitol Hill. June 2009, Tysons Corner, Virginia (Poster). *Neurology* 2009; 73(11), e54-456.
8. Brodsky JL, D’aco K, **Coughlin C**, Ficicioglu C, Pyeritz R, Levine MA. Bone Mineral Density in Patients with Homocystinuria. Presented at the annual meeting of the American Society of Human Genetics. Nov 2010, Washington DC. (Poster)
9. Sampson MG, **Coughlin CR 2nd**, Meyers KEC, Zackai EH, Kaplan P, Spinner NB, Copelovitch L. Evidence for a new locus on chromosome 16p11.2 associated with a syndrome of Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) and Hirschsprung Disease. Presented at The Fifteenth Congress of International Pediatric Nephrology Association. Aug-Sept 2010, New York, New York (Poster). *Pediatric Nephrology* 2010; 25(9):1912.
10. Falk MJ, Venkatasubramanian A, Mascherenas M, Place E, **Coughlin C 2nd**, Medne L, Thiel B, Spinner N, Bonnemann C. *MEF2C* haploinsufficiency causes static encephalopathy with myotonic epilepsy. Presented at the annual meeting of the American College of Medical Genetics. Mar 2010, Albuquerque, New Mexico. (Poster)
11. Mulchandani S, Conlin LK, Theil B, **Coughlin CR 2nd**, Hakonarson H, Zackai EH, Ganesh J, Deardorff MA, Spinner NB. SNP Array Diagnoses Involving Uniparental disomy (UPD) and Regions of Homozygosity (ROH). Presented at the annual meeting of the American College of Medical Genetics. Mar 2010, Albuquerque, New Mexico. (Poster)
12. Ganesh J, **Coughlin CR**, Fitzgerald K, Hanna B, Goldmuntz E, Shaddy R, Kaufman B. Comprehensive approach to Pediatric Cardiomyopathy – A 4-year experience in a single center. Presented at the annual meeting of the American College of Medical Genetics. Mar 2010, Albuquerque, New Mexico (Platform)
13. **Coughlin CR 2nd**, Hyland K, Randall R, Ficicioglu C. Dihydropteridine reductase deficiency and treatment with tetrahydrobiopterin: A case report. Presented at the 34th annual meeting of the Society for Inherited Metabolic Disorders. Feb-Mar 2011, Pacific Grove, California (Poster) *Mol Genet Metab* 2011 Mar;102:275.

14. **Coughlin CR 2nd**, Ficicioglu C. Pregnancy and Cobalamin C deficiency: A patient presenting with elevated Homocysteine and MMA levels following two spontaneous abortions. Presented at the 34th annual meeting of the Society for Inherited Metabolic Disorders. Feb-Mar 2011, Pacific Grove, California (Poster). *Mol Genet Metab* 2011; 102(3): 275-276.
15. Brodsky J, D'Aco K, **Coughlin C**, Ficicioglu C, Pyeritz R, Levine M. Bone mineral density deficits in patients with homocystinuria. Presented at the 11th European Congress on Osteoporosis and Osteoarthritis and International Liver Congress 2011. Mar 2011, Valencia, Spain (Poster). *Osteoporosis International* 2011; 22:135-136.
16. van Karnebeek CDM, Hartmann H, Jaggumantri S, Bok L, Cheng B, Connolly M, **Coughlin CR 2nd**, Das AM, Gospe, Jr SM, Jakobs C, van der Lee H, Mercimek-Mahmutoglu S, Meyer U, Struys E, Sinclair G, Van Hove J, Collet JP, Plecko BR, Stockler S. Lysine restricted diet for pyridoxine dependent epilepsy: First evidence & future trials. Presented at the Society for the Study of Inborn Errors of Metabolism annual symposium. Sept 2012, Birmingham, United Kingdom (Poster)
17. Golden-Grant KL, Scharer G, Walton CS, **Coughlin CR 2nd**. Whole exome sequencing: Are we ready? Presented at the National Society of Genetic Counselors 31st Annual Education Conference. Oct 2012, Boston, Massachusetts (Poster)
18. Scharer G, Creadon-Swindell G, Spector E, **Coughlin C**, Shaikh T. Single exon deletion in PCCA gene in a patient with Propionic Acidemia highlights challenges to clinical whole exome CNV analysis. Presented at the 62nd Annual Meeting of The American Society of Human Genetics. Nov 2012, San Francisco, California (Poster)
19. Yu H, **Coughlin CR 2nd**, Giger EA, Medne L, Ming JE, Zackai EH, Van Hove JL, Scharer GH, Shaikh TH. Family matters: Exome sequencing can identify causal variants in isolated probands through family studies. Presented at the 62nd Annual Meeting of The American Society of Human Genetics. Nov 2012, San Francisco, California. (Poster)
20. Sloan JL, Yu HC, Scharer G, Brebner A, Quintana A, Achilly NP, Manoli I, **Coughlin CR 2nd**, Geiger EA, Schneck U, Watkins D, Van Hove JL, Fowler B, Baumgartner MR, Rosenblat D, Venditti CP, Shaikh TH. Mutations in a transcription regulator cause a novel X-linked cobalamin disorder (*cbIX*) with a severe neurological phenotype. Presented at the International Congress of Inborn Errors of Metabolism. Sept 2013, Barcelona, Spain (Platform)
21. Friederich MW, Chatfield KC, **Coughlin CR 2nd**, Thomas JA, Gallagher RC, Lovell MA, Wanders RJA, Wartchow EP, Van Hove JLK. Mitochondrial energy failure in HSD10 disease also known as 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is secondary to defective mtRNA processing. Presented at the International Congress of Inborn Errors of Metabolism. Sept 2013, Barcelona Spain (Platform)
22. Yu HC, Sloan JL, Scharer G, Brebner A, Quintana A, Achilly NP, Manoli I, **Coughlin CR 2nd**, Geiger EA, Schneck U, Watkins D, Van Hove JL, Fowler B, Baumgartner MR, Rosenblat D, Venditti CP, Shaikh TH. Mutations in *HCFC1* a transcription coregulator causes a novel X-linked cobalamin disorder (*cbIX*) with a severe neurological phenotype. Presented at 63rd Annual Meeting of The American Society of Human Genetics. Oct 2013, Boston, Massachusetts (Platform)
23. Shuen AY, **Coughlin CR 2nd**, Lefrancois M, Srour M, Thomas JA, Gallagher RC, Waters PJ, Hyland K, Van Hove JL, Al-Hertani W. Combined triple therapy trial of pyridoxine, lysine restricted diet and arginine supplementation in four patients with pyridoxine-

- dependent epilepsy. Presented at 37th Annual Meeting of The Society of Inherited Metabolic Diseases, Mar 2014, Asilomar, California (Platform). *Molecular Genetics and Metabolism* 2014 Feb; 111(3): 234.
24. **Coughlin CR 2nd**, Aradhya S, Manchester D, Gallagher RC. Copy Number loss Proximal to the coding region of the ornithine transcarbamylase (OTC) gene confers severe neonatal OTC deficiency (OTCD): The first report that a distant mutation can confer OTCD. Presented at 37th Annual Meeting of The Society of Inherited Metabolic Diseases, Mar 2014, Asilomar, California (Poster). *Mol Genet Metab* 2014 Feb; 111(3):255.
 25. Van Hove JL, Swanson MA, **Coughlin CR 2nd**, Bjoraker K, Spector E, Scharer G, Creadon-Swindell G, Mahieu V, Matthijs G, Hennermann J. Outcome in nonketotic hyperglycinemia. Presented at 37th Annual Meeting of The Society of Inherited Metabolic Diseases, Mar 2014, Asilomar, California (Platform). *Molecular Genetics and Metabolism* 2014; 111(3):238-239.
 26. van Karnebeek C, Al-Hertani W, Jaggumantri S, **Coughlin C**, Gallagher R, Van Hove J, Stockler S, Hartmann H. Update on novel treatments for Pyridoxine-Dependent Epilepsy due to ATQ deficiency. Presented at the Meeting of Society for the Study of Inborn Errors of Metabolism, Sept 2014, Innsbruck Austria (Platform)
 27. Van Hove JL, Swanson MA, **Coughlin CR 2nd**, Szerlong H, Bjoraker K, Spector E, Scharer G, Creadon-Swindell G, Suhong T, Mahieu V, Matthijs G, Hennermann J. Outcome in nonketotic hyperglycinemia. Presented at the Child Neurology Society 43rd Annual Meeting, Oct 2014, Columbus, Ohio (Platform). *Annals of Neurology* 2014; 76:S178-S179.
 28. van Karnebeek CDM, Al-Hertani W, Jaggumantri S, **Coughlin C**, Stockler S, Hans Hartmann H, Van Hove J. Update on novel treatments for pyridoxine dependent epilepsy due to antiquitin deficiency. Presented at the 38th Annual meeting of the Canadian College of Medical Geneticists, Nov 2014, Vancouver, British Columbia (Poster). *J Med Genet* 2015; 52(Suppl 1): A9.
 29. Larson A, Stence NV, **Coughlin CR 2nd**, Thomas JA, Gallagher RC, Collins A, Van Hove JKL. Improvement of the pathological findings on magnetic resonance imaging of the brain with the use of ketogenic diet for pyruvate dehydrogenase complex deficiency. Presented at the 38th Annual Meeting of The Society of Inherited Metabolic Diseases, Mar 2015, Salt Lake City, Utah (Poster). *Mol Genet Metab* 2015 Mar; 114(3):356.
 30. Stence N, Fenton L, **Coughlin C**, Van Hove J. Predictable Progression of Restricted Diffusion in Nonketotic Hyperglycinemia. Presented at the American Society of Neuroradiology 53rd Annual Meeting, Apr 2015, Chicago, Illinois (Platform)
 31. **Coughlin CR 2nd**, van Karnebeek CDM, Jaggumantri S, Al-Hertani W, Shuen AY, Jack RM, Gaughan S, Burns C, Gallagher RC, Mirsky DM, Van Hove JKL. Triple therapy (Arginine fortification + Lysine Restricted Diet + Pyridoxine) for pyridoxine dependent epilepsy. Presented at the Garrod Symposium, May 2015, Vancouver, British Columbia (Platform)
 32. Jaggumantri S, **Coughlin C**, Stockler S, Barb C, Mary C, Van Hove J, van Karnebeek C. 2015 update on triple therapy for pyridoxine-dependent epilepsy. Presented at the 50th Annual Congress of the Canadian Neurologic Sciences Federation, June 2015, Toronto, Ontario (Platform). *Canadian Journal of Neurological Sciences*. May 2015; 42(S1):S13.
 33. Ferdinandusse S, Friederich MW, Burlina A, Ruiten JPN, **Coughlin CR 2nd**, Dishop MK, Gallagher RC, Bedoyan JK, Vaz FM, Waterham HR, Elpeleg O, Gowan K, Chatfield K, Van Hove JKL, Wanders RJA. Clinical and biochemical characterization of four patients with

- mutations in *ECHS1*. Presented at the 47th annual European Metabolic Group conference, June 2015, Venice, Italy (Poster)
34. Friederich MW, **Coughlin CR 2nd**, O'Rourke C, Lovell MA, Gowan K, Van Hove LK. Mutations in *NDUFB10* results in isolated complex I deficiency due to incomplete assembly of complex I holoenzyme. Presented at Mitochondrial Medicine 2015, June 2015, Washington DC (Poster). *Mitochondrion* 2015 Sept; 24:S26.
 35. Scalais E, Weitzel C, De Meirleir L, Martens G, Shaikh T, **Coughlin CR 2nd**, Yu HC, Swanson M, Friederich M, Scharer G, Helbling D, Wendt-Andrea J, Acquaviva-Bourdain C, Van Hove J. Cobalamin X (HCFC1 deficiency) mimicking nonketotic hyperglycinemia (NKH) with increased CSF glycine and methylmalonic acid. Presented at the Society for the Study of Inborn Errors of Metabolism, Sept 2015, Lyon, France (Poster)
 36. Faucett A, Rashkin M, Brothers K, **Coughlin C**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Savage Stosic M, Smith M, Uhlmann W, Wain K, Ormond K. Preliminary Discussions in the Development of Recommendation for Ordering Clinicians with Minimal Genetics Background: intro to the Consent and Disclosure Recommendations (CADRe) committee. Presented at the National Society of Genetic Counselors 34th Annual Education Conference. Oct 2015, Pittsburgh, Pennsylvania (Poster)
 37. Nguyen TP, Karimpour-Fard A, **Coughlin CR 2nd**, Chatfield KC. MicroRNAs as a Marker of Cardiovascular Disease in Marfan Syndrome and Marfan-related Disorders. Presented at the National Society of Genetic Counselors 34th Annual Education Conference. Oct 2015, Pittsburgh, Pennsylvania (Poster)
 38. Yu HC, **Coughlin CR 2nd**, Geiger EA, Elias ER, Cavanaguh JL, Miyamoto SD, Shaikh TH. Discovery of a deleterious variant in *TMEM87B* in a patient with a hemizygous 2q13 microdeletion, uncovers a recessive condition characterized by severe congenital heart defects. Presented at 65th Annual Meeting of the American Society of Human Genetics. Oct 2015, Baltimore, Maryland (Poster)
 39. **Coughlin CR 2nd**, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Kure S, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Scharer GH, Van Hove JLK. The genotypic spectrum of classic nonketotic hyperglycinemia due to mutations in *GLDC* and *AMT*. Presented at the ACMG Annual Clinical Genetic Meeting. Mar 2016, Tampa, Florida (Platform)
 40. **Coughlin CR 2nd**, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Kure S, Väisänen ML, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Rahikkala E, Moilanen J, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vinaey-Saban C, Scharer GH, Van Hove JLK. The genotypic spectrum of classic nonketotic hyperglycinemia due to mutations in *GLDC* and *AMT*. Presented at the 39th Annual Meeting of the Society for Inherited Metabolic Disorders. Apr 2016, Ponte Vedra Beach, Florida (Platform) *Mol Genet Metab* 2016 Mar;117:236.
 41. Woontner M, Goodman S, Schlichting L, Hawkins M, Noll L, Weisfeld-Adams J, **Coughlin C 2nd**. A patient with hyper-beta-alaninemia. Presented at the 39th Annual Meeting of the Society for Inherited Metabolic Disorders. Apr 2016, Ponte Vedra Beach, Florida (Poster) *Mol Genet Metab*, 2015 Mar 117; 294.
 42. Chen MA, Wortmann SB, Tiller GE, Wevers RA, Botto LD, **Coughlin CR**, Descartes M, Kyriss M, Maranda B, Pitt J, Potente C, Rodenburg R, Srirangan S, van Settend P, Thomas J, Vockley G, Waters PJ, Weber JL, White SM. Phenotypic Variability in UMPS Heterozygotes with Orotic Aciduria. Presented at the 39th Annual Meeting of the Society for

- Inherited Metabolic Disorders. Apr 2016, Ponte Vedra Beach, Florida (Poster) *Mol Genet Metab* 2016 Mar;117:250.
43. Ormond K, Hallquist M, Buchanan A, Cho M, Kaufman D, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Savage Stosic M, Smith M, Uhlmann W, Wain K, Faucett A. Development of Recommendations for Ordering Clinicians with Minimal Genetics Background from the ClinGen Consortium Consent and Disclosure Recommendations (CARDe) Committee. Presented at the European Meeting on Psychosocial Aspects of Genetics. May 2016, Barcelona, Spain (Platform)
 44. Larson A, Freidrich M, **Coughlin CR 2nd**, Van Hove JLK. 9032T>C is a new pathogenic variant in mtDNA resulting in impaired assembly of complex V. Presented at Mitochondrial Medicine 2016, June 2016, Seattle, Washington (Poster)
 45. Faucett WA, Hallquist M, Buchanan A, Cho M, Kaufman D, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann, Wain K, Ormond KE. The ClinGen CADRe Rubric: Developing Communication Strategies for Actionable Genes. Presented at the 2016 ClinGen/DECIPHER conference. June 2016, Cambridge, England (Poster)
 46. Faucett WA, Hallquist M, Buchanan A, Cho M, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann W, Wain K, Ormond KE. Development of tools to determine communication strategies for actionable genes from ClinGen's CARDe working group. Presented at the National Society of Genetic Counselors 35th Annual Education Conference. Sept-Oct 2016, Seattle, Washington (Poster)
 47. Buchanan AH, Faucett WA, Hallquist M, Cho M, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann W, Wain K, Ormond KE. Genetic testing for hereditary cancer predisposition: Can a targeted discussion with a non-genetics clinician provide adequate consent? Presented at the National Society of Genetic Counselors 35th Annual Education Conference. Sept-Oct 2016, Seattle, Washington (Poster)
 48. Larson AA, Quintana AM, Yu HC, Geiger EA, Hernandez JA, Stence NV, Kuzniecky RI, Shaikh TH, **Coughlin CR 2nd**, Meeks NJL. Mutations in *RALGAPB* cause seizures, intellectual disability and cortical malformations. Presented at the 66th Annual Meeting of The American Society of Human Genetics, Oct 2016, Vancouver, Canada. (Poster)
 49. Hallquist M, Buchanan A, Faucett WA, Cho M, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Jamal S, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann W, Wain K, Ormond KE. Determining critical communication issues for the genetic testing process. Presented at the 66th Annual Meeting of The American Society of Human Genetics, Oct 2016, Vancouver, Canada (Poster)
 50. Jaggamantri S, **Coughlin CR**, Al-Hertani W, Shuen, A, Jack RM, Burns C, Mirsky D, Gallagher R, van Karnebeek C, Van Hove J. Triple therapy (Arginine fortification + Lysine Restricted Diet + Pyridoxine) for pyridoxine dependent epilepsy. Presented at the 66th Annual Meeting of The American Society of Human Genetics, Oct 2016, Vancouver, Canada. (Poster)
 51. Mostovoy Y, Levy-Sakin M, Lam J, Lam ET, Hastie AR, Marks P, Lee J, Chu C, Lin C, Džakula Z, Cao H, Schlebusch SA, Giorda K, Schnall-Levin M, Wall JD, Meeks NJL, Chatfield KC, **Coughlin CR 2nd**, Shaikh TH, Kwok P. A hybrid approach for *de novo* human genome sequence assembly, phasing, and detection of complex structural variation.

- Presented at the 66th Annual Meeting of The American Society of Human Genetics, Oct 2016, Vancouver, Canada. (Platform)
52. Reyes N, Yu HC, **Coughlin C 2nd**, Shaikh T, Herenandez J, Quintana A. Mutations in GABRA1 cause multiple congenital anomaly syndrome characterized by a severe seizure phenotype. Presented at the Summer COURI Symposia, Aug 2016, El Paso, Texas (Poster)
 53. Reyes N, Yu HC, **Coughlin C 2nd**, Shaikh T, Herenandez J, Quintana A. Mutations in GABRA1 cause multiple congenital anomaly syndrome characterized by a severe seizure phenotype. Presented at the Annual Biomedical Research Conference for Minority Students, Nov 2016, Tampa, Florida (Platform)
 54. Reyes-Nava N, Yu HC, **Coughlin CR 2nd**, Shaikh TH, Herenandez JA, Quintana AM. Functional analysis of GABRA1 in zebrafish. Presented at the 3rd Border Biomedical Research Center Symposium, Sept 2017, El Paso, Texas (Poster)
 55. Stence NV, Fenton LZ, Palmer C, Tong S, **Coughlin CR 2nd**, Hennermann J, Wortmann SB, Van Hove JLK. Brain imaging in classic nonketotic hyperglycinemia. Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Mar 2018, San Diego, California. (Poster) *Mol Genet Metab* 2018 Mar;123:266-7.
 56. **Coughlin CR 2nd**, Swanson MA, Spector E, Meeks NJ, Kronquist K, Tsai BP, Strom SP, Gao H, Nagy P, Hyland K, van Dooren SJ, Salomons GS, Van Hove JLK. The genotypic spectrum of ALDH7A1 mutations resulting in pyridoxine dependent epilepsy. Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Mar 2018, San Diego, California. (Poster) *Mol Genet Metab* 2018 Mar;123:224.
 57. Hallquist MLG, Ormond KE, Tricou EP, Faucett WA, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann W, Wain K, Buchanan AH. Consent for genetic testing and disclosure of results: Shifting the paradigm to non-genetics clinicians. Presented at the Annual American College of Medical Genetics Clinical Genetics Meeting, Apr 2018, Charlotte, North Carolina. (Platform)
 58. Ormond KE, Hallquist MLG, Tricou EP, Faucett WA, Brothers K, **Coughlin CR 2nd**, Hercher L, Hudgins L, Levy H, Peay H, Roche M, Stosic M, Smith M, Uhlmann W, Wain K, Buchanan AH. Consent for genetic testing and disclosure of results: Shifting the paradigm to non-genetics clinicians. Presented at the European Meeting on Psychosocial Aspects of Genetics, June 2018, Milan, Italy. (Platform)
 59. Reyes-Nava N, Yu HC, **Coughlin CR 2nd**, Shaikh TH, Quintana AM. Knockdown of the zebrafish orthologue of GABRA1 results in absence seizures. Presented at the Society for Developmental Biology 77th Annual Meeting, July 2018, Portland, Oregon. (Poster)
 60. Castellanos BS, **Coughlin C 2nd**, Yu HC, Shaikh TH, Quintana AM. Using zebrafish as a model to understand the role of HSPG2 in early craniofacial development. Presented at the Society for Developmental Biology 77th Annual Meeting, July 2018, Portland, Oregon. (Poster)
 61. Yilmaz F, Mostovoy Y, Geiger EA, Meeks NJL, Chatfield KC, **Coughlin CR 2nd**, Kwok P, Shaikh TH. A next-generation mapping approach for the assembly and detection of structural variation within genomic regions containing complex segmental duplications. Presented at the Annual Meeting of the American Society of Human Genetics, Oct 2018, San Diego, California. (Poster)
 62. Reyes-Nava, Yu HC, **Coughlin CR 2nd**, Shaikh TH, Quintana AM. *Gabra1* disrupts normal brain development in a zebrafish model of hypomotility. Presented at the Southwest Regional Society for Developmental Biology Meeting, March 2019, Denver, Colorado. (Poster)

63. Tseng LA, Gospe SM Jr, Aziz VG, Bok LA, Hartmann H, Kurlemann G, **Coughlin CR 2nd**, van Karnebeek CD, Pyridoxine-dependent epilepsy in adulthood. Presented at Annual Symposium of the Society for the Study of Inborn Errors of Metabolism, Sept 2019, Rotterdam, The Netherlands. (Poster)
64. Woontner M, **Coughlin C 2nd**, Goodman S. Novel biomarkers of late-onset ornithine transcarbamylase deficiency. Presented at the 42nd Annual Meeting of the Society for Inherited Metabolic Disorders, Apr 2020, Austin, Texas. (Poster)
* *Meeting cancelled due to the novel coronavirus disease COVID-19*
65. Ormond K, Borenstein M, Buchanan A, Cho M, **Coughlin CR 2nd**, Faucett A, Hallquist M, Peay H, Smith M, Stosic M, Tricou E, Uhlmann W, Wain K. Targeted consent discussions for genetic testing – a consensus study to define relevant elements. Presented at the 5th ELSI Congress, June 2020, New York, New York. (Flash presentation)
* *Meeting cancelled due to the novel coronavirus disease COVID-19*
66. Ormond KE, Borenstein M, Buchanan AH, Faucett WA, Hallquist MLG, Peay HL, Smith ME, Tricou EP, Uhlmann WR, Wain K, **Coughlin CR 2nd**. Critical components of informed consent for genetic testing: Results of a Delphi Consensus process. Presented at the European Human Genetics Conference, June 2020, Berlin, Germany. (Oral presentation).
67. Borenstein M, Hallquist M, **Coughlin CR 2nd**, Buchanan A, Faucett WA, Peay H, Smith ME, Tricou E, Uhlmann W, Wain K, Ormond KE. Defining the critical components of informed consent for genetic testing. Presented at the National Society of Genetic Counselors 39th Annual Education Conference. Nov 2020, Nashville, Tennessee. (Poster)
68. Baker II PR, Ables H, Bedoyan J, Feldman G, Keegan C, Lichter-Konecki U, Longo N, McDonald M, Merideth M, Venditti C, Merritt L, Shinawi M, Sutton R, Vernon H, Wilcox W, El-Gharbawy A, Koeller D, Steiner R, Barshop B, **Coughlin C II**, Koacchar A, Van Hove J, Thomas J, Larson A, McCandless S. Opportunities for fellowship education: The first year of the medical biochemical genetics clinic core seminar series. Presented at the ACMG Annual Clinical Genetics Meeting. April 2021. Virtual conference. (Platform presentation)
69. Tseng LA, Abdenur JE, Anderws A, Aziz VG, Bok LA, Boyer M, Buhas D, Hartmann H, Fooitt EJ, Grønberg S, Janssen MCH, Longo N, Lunsing RJ, Wijburg FA, Gospe SM Jr, **Coughlin CR 2nd**, van Karnebeek CDM. Association between early treatment and neurodevelopmental outcome in 18 families with PDE-ALDH7A1. Presented at the 14th International Congress of Inborn Errors of Metabolism. Nov 2021, Sydney, Australia. (Platform presentation)
70. Micke K, Elfman H, Jones K, **Coughlin C**, Reynolds R, Larson A, McCandless S, Behrendt N, Galan HL, Zaretsky M. Integrating whole exome sequencing into prenatal care: piloting a multidisciplinary approach. Presented at the 42nd Annual Pregnancy Meeting for the Society for Maternal-Fetal Medicine. Jan-Feb 2022, Orlando, Florida.

Media appearances

1. “Designer babies: The genetic editing experiment.” *Denver 7 News*, American Broadcast Company. Originally broadcast on 28 November 2018.
 - Available at: <https://www.thedenverchannel.com/news/360/designer-babies-the-genetic-editing-experiment-that-has-caused-recent-controversy>
2. “Pyridoxine-dependent epilepsy.” The JIMD Podcast. January 2021
 - Available at: <https://onlinelibrary.wiley.com/page/journal/15732665/podcasts> and <https://soundcloud.com/user-109006120>